These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23697050)

  • 1. [An advance in the management of breast cancer].
    Soins; 2013 Apr; (774):12. PubMed ID: 23697050
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential role of mammalian target of rapamycin inhibitors in breast cancer therapy.
    Meric-Bernstam F; Esteva FJ
    Clin Breast Cancer; 2005 Oct; 6(4):357-60. PubMed ID: 16277888
    [No Abstract]   [Full Text] [Related]  

  • 3. [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
    Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming endocrine resistance in breast cancer: importance of mTOR inhibition.
    Gnant M
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1579-89. PubMed ID: 23253223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in HR-positive advanced breast cancer.
    Tartarone A; Lerose R; Aieta M
    N Engl J Med; 2012 May; 366(18):1739; author reply 1739-40. PubMed ID: 22551140
    [No Abstract]   [Full Text] [Related]  

  • 6. Everolimus in HR-positive advanced breast cancer.
    Massarweh S; Croley J; Weiss H
    N Engl J Med; 2012 May; 366(18):1738-9; author reply 1739-40. PubMed ID: 22551139
    [No Abstract]   [Full Text] [Related]  

  • 7. Are we missing the mTOR target in breast cancer?
    Johnston SR
    Breast Cancer Res Treat; 2011 Aug; 128(3):607-11. PubMed ID: 20953834
    [No Abstract]   [Full Text] [Related]  

  • 8. Maintenance therapy in the treatment of sarcoma.
    Ray-Coquard I
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):773-4. PubMed ID: 22252579
    [No Abstract]   [Full Text] [Related]  

  • 9. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer.
    Chollet P; Abrial C; Tacca O; Mouret-Reynier MA; Leheurteur M; Durando X; Curé H
    Clin Breast Cancer; 2006 Oct; 7(4):336-8. PubMed ID: 17092402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
    Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
    Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BOLERO-2 - will this change practice in advanced breast cancer?
    Johnston SR
    Breast Cancer Res; 2012 Jun; 14(3):311. PubMed ID: 22713135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives in central nervous system malignancies.
    Stummer W
    IDrugs; 2006 Jun; 9(6):412-4. PubMed ID: 16752310
    [No Abstract]   [Full Text] [Related]  

  • 13. A meta-analysis of randomized controlled trials comparing chemotherapy plus trastuzumab with chemotherapy alone in HER-2-positive advanced breast cancer.
    Liao C; Yin F; Huang P; Cao Y; Gao F
    Breast J; 2011; 17(1):109-11. PubMed ID: 21129096
    [No Abstract]   [Full Text] [Related]  

  • 14. [Update on clinical activity of CCI779 (temsirolimus), mTOR inhibitor].
    Mounier N; Vignot S; Spano JP
    Bull Cancer; 2006 Nov; 93(11):1139-43. PubMed ID: 17145584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy.
    Chlebowski RT
    J Natl Cancer Inst; 2010 Jan; 102(2):137. PubMed ID: 20019336
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
    Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
    Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?
    Zardavas D; Fumagalli D; Loi S
    Curr Opin Oncol; 2012 Nov; 24(6):623-34. PubMed ID: 22960556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mammalian target of rapamycin inhibitor everolimus (RAD001) in early breast cancer: results of a pre-operative study.
    Macaskill EJ; Bartlett JM; Sabine VS; Faratian D; Renshaw L; White S; Campbell FM; Young O; Williams L; Thomas JS; Barber MD; Dixon JM
    Breast Cancer Res Treat; 2011 Aug; 128(3):725-34. PubMed ID: 20941539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.